Metage2Metabo, microbiota-scale metabolic complementarity for the identication of key species
- Univ Rennes, Inria, CNRS, IRISA, France
- Inria, France
- INRAE, UMR IGEPP, France
- Quadram Institute, United Kingdom
Abstract
To capture the functional diversity of microbiota, one must identify metabolic functions and species of interest within hundreds or thousands of microorganisms. We present Metage2Metabo (M2M) a resource that meets the need for de-novo functional screening of genome-scale metabolic networks (GSMNs) at the scale of a metagenome, and the identification of critical species with respect to metabolic cooperation. M2M comprises a flexible pipeline for the characterisation of individual metabolisms and collective metabolic complementarity. In addition, M2M identifies key species, that are meaningful members of the community for functions of interest. We demonstrate that M2M is applicable to collections of genomes as well as metagenome-assembled genomes, permits an efficient GSMN reconstruction with Pathway Tools, and assesses the cooperation potential between species. M2M identifies key organisms by reducing the complexity of a large-scale microbiota into minimal communities with equivalent properties, suitable for further analyses.
Data availability
Data for metabolic modelling is available in https://github.com/AuReMe/metage2metabo/tree/master/article_data .
-
Assembly of 913 microbial genomes from metagenomic sequencing of the cow rumen.European Nucleotide Archive, PRJEB21624.
-
Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota.European Nucleotide Archive PRJEB1786, PRJEB4336, PRJEB5224.
Article and author information
Author details
Funding
BBSRC (Gut Microbes and Health BB/r012490/1,and its constituent project BBS/e/F/000Pr1035)
- Clémence Frioux
- Falk Hildebrand
2 (IDEALG (ANR-10-BTBR-04) Investissements d'Avenir)
- Arnaud Belcour
- Clémence Frioux
- Méziane Aite
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Copyright
© 2020, Belcour et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 5,812
- views
-
- 607
- downloads
-
- 51
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Metage2Metabo, microbiota-scale metabolic complementarity for the identication of key species
eLife 9:e61968.
https://doi.org/10.7554/eLife.61968
Further reading
-
- Computational and Systems Biology
- Microbiology and Infectious Disease
Antimicrobial resistance is responsible for an alarming number of deaths, estimated at 5 million per year. To combat priority pathogens, like Helicobacter pylori, the development of novel therapies is of utmost importance. Understanding the molecular alterations induced by medications is critical for the design of multi-targeting treatments capable of eradicating the infection and mitigating its pathogenicity. However, the application of bulk omics approaches for unraveling drug molecular mechanisms of action is limited by their inability to discriminate between target-specific modifications and off-target effects. This study introduces a multi-omics method to overcome the existing limitation. For the first time, the Proteome Integral Solubility Alteration (PISA) assay is utilized in bacteria in the PISA-Express format to link proteome solubility with different and potentially immediate responses to drug treatment, enabling us the resolution to understand target-specific modifications and off-target effects. This study introduces a comprehensive method for understanding drug mechanisms and optimizing the development of multi-targeting antimicrobial therapies.
-
- Computational and Systems Biology
To help maximize the impact of scientific journal articles, authors must ensure that article figures are accessible to people with color-vision deficiencies (CVDs), which affect up to 8% of males and 0.5% of females. We evaluated images published in biology- and medicine-oriented research articles between 2012 and 2022. Most included at least one color contrast that could be problematic for people with deuteranopia (‘deuteranopes’), the most common form of CVD. However, spatial distances and within-image labels frequently mitigated potential problems. Initially, we reviewed 4964 images from eLife, comparing each against a simulated version that approximated how it might appear to deuteranopes. We identified 636 (12.8%) images that we determined would be difficult for deuteranopes to interpret. Our findings suggest that the frequency of this problem has decreased over time and that articles from cell-oriented disciplines were most often problematic. We used machine learning to automate the identification of problematic images. For a hold-out test set from eLife (n=879), a convolutional neural network classified the images with an area under the precision-recall curve of 0.75. The same network classified images from PubMed Central (n=1191) with an area under the precision-recall curve of 0.39. We created a Web application (https://bioapps.byu.edu/colorblind_image_tester); users can upload images, view simulated versions, and obtain predictions. Our findings shed new light on the frequency and nature of scientific images that may be problematic for deuteranopes and motivate additional efforts to increase accessibility.
